Patients with coronavirus disease 2019 (COVID-19) have a wide variety of clinical outcomes ranging from asymptomatic to severe respiratory syndrome that can progress to life-threatening lung lesions. The identification of prognostic factors can help to improve the risk stratification of patients by promptly defining for each the most effective therapy to resolve the disease. The etiological agent causing COVID-19 is a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that enters cells via the ACE2 receptor. SARS-CoV-2 infection causes a reduction in ACE2 levels, leading to an imbalance in the renin-angiotensin system (RAS), and consequently, in blood pressure and systemic vascular resistance. ERAP1 and ERAP2 are two RAS regulators and key components of MHC class I antigen processing. Their polymorphisms have been associated with autoimmune and inflammatory conditions, hypertension, and cancer. Based on their involvement in the RAS, we believe that the dysfunctional status of ERAP1 and ERAP2 enzymes may exacerbate the effect of SARS-CoV-2 infection, aggravating the symptomatology and clinical outcome of the disease. In this review, we discuss this hypothesis.

D'Amico, S., Tempora, P., Lucarini, V., Melaiu, O., Gaspari, S., Algeri, M., et al. (2021). ERAP1 and ERAP2 enzymes: A protective shield for ras against COVID-19?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(4), 1-10 [10.3390/ijms22041705].

ERAP1 and ERAP2 enzymes: A protective shield for ras against COVID-19?

Melaiu O.;
2021

Abstract

Patients with coronavirus disease 2019 (COVID-19) have a wide variety of clinical outcomes ranging from asymptomatic to severe respiratory syndrome that can progress to life-threatening lung lesions. The identification of prognostic factors can help to improve the risk stratification of patients by promptly defining for each the most effective therapy to resolve the disease. The etiological agent causing COVID-19 is a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that enters cells via the ACE2 receptor. SARS-CoV-2 infection causes a reduction in ACE2 levels, leading to an imbalance in the renin-angiotensin system (RAS), and consequently, in blood pressure and systemic vascular resistance. ERAP1 and ERAP2 are two RAS regulators and key components of MHC class I antigen processing. Their polymorphisms have been associated with autoimmune and inflammatory conditions, hypertension, and cancer. Based on their involvement in the RAS, we believe that the dysfunctional status of ERAP1 and ERAP2 enzymes may exacerbate the effect of SARS-CoV-2 infection, aggravating the symptomatology and clinical outcome of the disease. In this review, we discuss this hypothesis.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/05
English
COVID-19
ERAP1
ERAP2
renin–angiotensin system
risk factor
Age Factors
Aminopeptidases
Angiotensin-Converting Enzyme 2
Antigen Presentation
COVID-19
Female
Humans
Hypertension
Male
Minor Histocompatibility Antigens
Polymorphism, Single Nucleotide
SARS-CoV-2
Sex Factors
Virus Internalization
Renin-Angiotensin System
D'Amico, S., Tempora, P., Lucarini, V., Melaiu, O., Gaspari, S., Algeri, M., et al. (2021). ERAP1 and ERAP2 enzymes: A protective shield for ras against COVID-19?. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(4), 1-10 [10.3390/ijms22041705].
D'Amico, S; Tempora, P; Lucarini, V; Melaiu, O; Gaspari, S; Algeri, M; Fruci, D
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/305977
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact